Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

806 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2018-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is determine safety and effectiveness of Neutrolin, a catheter lock solution, for prevention of central venous catheter associated bloodstream infection in hemodialysis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Effectiveness and Safety of Three Lock Solutions for Long-Term Central Venous Catheter for Hemodialysis

NCT02618317

Chronic Kidney Disease

COMPLETED PHASE4

Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia

NCT00294502

ESRD

COMPLETED PHASE4

A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia

NCT00614679

End-Stage Renal Disease Hemodialysis Catheter-associated Infection

COMPLETED PHASE1

The Effectiveness and Safety of 4% Sodium Citrate as a Lock Solution in Central Venous Hemodialysis Catheter

NCT05188339

Central Venous Catheter Thrombosis Renal Dialysis

UNKNOWN PHASE2/PHASE3

Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections

NCT01483872

Infection; Dialysis Catheter

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to demonstrate the efficacy and safety of Neutrolin® as a catheter lock solution (CLS) on prevention of catheter-related bloodstream infection (CRBSI), and the incidence of treatment-emergent adverse events in subjects receiving hemodialysis (HD) for the treatment of End Stage Renal Disease (ESRD) when compared with heparin 4,000 USP Units/4mL (1,000 USP Units/mL).

This is a randomized, double-blind, active control, parallel-arm, multicenter study. Six hundred and thirty two subjects will be randomized in a 1:1 ratio to receive either Neutrolin® or the active control heparin (Heparin sodium USP 1,000 units/mL, Benzyl alcohol 9.45 mg/mL and Sodium chloride 9.0 mg/mL) as a CLS.

Approximately 632 randomized subjects are planned for this trial. In this study, one-half of the subjects (316 subjects) will receive Neutrolin as a study drug and the other half will receive heparin 4,000 USP Units/4mL (1,000 USP Units/mL) with benzyl alcohol preservative as a comparator. Subjects will be assigned in a 1:1 ratio using permuted blocks without additional stratification for both groups.

The primary objective of this study is to demonstrate the effectiveness of Neutrolin® as a CLS in ESRD subjects undergoing HD treatment using a permanent, cuffed, tunneled silicone or polyurethane HD catheter. The study will evaluate whether Neutrolin® is superior to the active control heparin by documenting the time to CRBSI and consequently delaying the time until the occurrence of CRBSI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Failure, Chronic Catheter-Related Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neutrolin arm

Neutrolin: Neutrolin will be added to the central venous catheter after dialysis as a lock solution

Group Type EXPERIMENTAL

Neutrolin

Intervention Type DRUG

Neutrolin® will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session

Heparin arm

Heparin: Heparin will be added to the central venous catheter after dialysis as a lock solution

Group Type ACTIVE_COMPARATOR

Heparin

Intervention Type DRUG

Heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neutrolin

Neutrolin® will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session

Intervention Type DRUG

Heparin

Heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

1.35% taurolidine, 3.5% citrate, heparin 1,000 USP Units/mL Heparin Sodium

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject has ESRD and undergoes chronic HD at least two times per week
2. Subject has a HD catheter that has demonstrated the ability to achieve a minimum blood flow of at least 250 mL/min for at least two consecutive dialysis sessions blood flow to enable successful HD
3. The HD catheter is implanted with the tip in a jugular or subclavian vein
4. The subject is not expected to expire within 180 days
5. The subject is likely to require the use of a CVC for at least 90 days
6. The subject (or the legal guardian) understands the nature of the study and provides written informed consent prior to the study enrollment
7. The subject is willing to comply with specified follow-up evaluations and prescribed dialysis therapy and
8. If female and of childbearing potential, the subject must have a negative pregnancy test at the screening visit (i.e., subject is not pregnant); not be lactating; and use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or hormonal contraceptive (oral, implant, ring, patch) for the duration of the study. (NOTE: The subject must have used the chosen method of birth control for at least 1 month/cycle prior to enrollment into the study).

Exclusion Criteria

1. Subjects who received antibiotics within the last 14 days
2. Visible evidence of compromised skin integrity is present at the catheter exit site or evidence of a catheter exit site infection
3. Subject has received any thrombolytic treatment (i.e., tPA) in their current catheter within 30 days of randomization
4. Fill volume of HD catheter is unknown or cannot be determined
5. Subjects using any type of antimicrobial-coated or heparin-coated catheter
6. Documented chronic bleeding diathesis, active or recurrent bleeding within 1 month prior to randomization
7. Documented history of an atrial thrombus or known hypercoagulable state
8. Subjects with open, non-healing skin ulcers
9. Current requirement for systemic immunosuppression that would increase risk of infection
10. Active malignancy requiring or anticipated to require chemotherapy likely to cause leukopenia and/or immunosuppression
11. Known allergy or absolute contraindication to citrate, taurolidine or heparin or a history of heparin-induced thrombocytopenia
12. Unstable malignancy
13. Cirrhosis with encephalopathy
14. Subject is currently taking another medication with known systemic drug interaction with citrate, taurolidine, or heparin
15. Subject is currently enrolled in another investigational device and/or drug trial or has participated in another investigational device and/or drug trial within 30 days prior to enrollment
16. Subject is anticipated to receive a renal transplant within 90 days (subjects can be on the transplant list, but a subject with a known or anticipated transplant date within the next 90 days should be excluded)
17. Any other medical condition which renders the subject unable to or unlikely to complete the study, or which would interfere with optimal participation in the study or produce significant risk to the subject.

\-

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No